Lucid Diagnostics Inc. closed a public offering of 28,750,000 shares of its common stock at a price of $1.00 per share.
The offering included an additional 3,750,000 shares purchased by underwriters.
The total net proceeds from the offering are expected to be approximately $26.9 million.
Offering Details
Total of 28,750,000 common stock shares sold, with additional 3,750,000 shares underwriters' purchase.
Net Proceeds
Expected net proceeds from the offering estimated at around $26.9 million.
Use of Funds
Proceeds intended for working capital and general corporate purposes.
Underwriters
Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, while Maxim Group LLC was the co-manager.
Securities Offered
Offered under Form S-3 shelf registration statement (File No. 333-268560) declared effective on December 6, 2022.
- Lucid Diagnostics aims to use the raised funds for working capital and corporate needs, potentially supporting its cancer prevention diagnostic efforts.
- The successful closing of the public offering signifies investor confidence in Lucid Diagnostics' future prospects.
Lucid Diagnostics Inc. successfully closed its public offering, raising significant funds for its operations and future growth initiatives. The strong investor interest demonstrates the market's belief in the company's potential success in the cancer prevention medical diagnostics space.